Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data ...

One day before the potential FDA approval of an RSV rival from Merck, Sanofi has revealed an aggressive supply effort for its blockbuster Beyfortus.

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious disease R&D.

Sanofi to acquire Blueprint Medicines for about $9.1B The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

After signaling its intent to make "bolt-on acquisitions," Sanofi has taken a major plunge, buying out Blueprint Medicines for $9.5 billion.

Sanofi extended the deal again last year to cover another STAT6 degrader, and, two months ago, the French pharma paid out $15 million for the rights to a once-undruggable transcription factor.

ALAIN JOCARD/AFP via Getty Images Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases.

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.